- Home
- VRAX vs EVAX Comparison
VRAX vs EVAX Comparison
Compare VRAX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- EVAX
- Stock Information
- Founded
- VRAX 2013
- EVAX 2008
- Country
- VRAX United Kingdom
- EVAX Denmark
- Employees
- VRAX N/A
- EVAX N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRAX Health Care
- EVAX Health Care
- Exchange
- VRAX Nasdaq
- EVAX Nasdaq
- Market Cap
- VRAX 4.4M
- EVAX 17.8M
- IPO Year
- VRAX 2022
- EVAX 2021
- Fundamental
- Price
- VRAX $0.64
- EVAX $3.00
- Analyst Decision
- VRAX Strong Buy
- EVAX Strong Buy
- Analyst Count
- VRAX 1
- EVAX 2
- Target Price
- VRAX $3.00
- EVAX $10.00
- AVG Volume (30 Days)
- VRAX 1.6M
- EVAX 63.4K
- Earning Date
- VRAX 01-01-0001
- EVAX 10-30-2025
- Dividend Yield
- VRAX N/A
- EVAX N/A
- EPS Growth
- VRAX N/A
- EVAX N/A
- EPS
- VRAX N/A
- EVAX N/A
- Revenue
- VRAX $6,331.00
- EVAX $3,176,000.00
- Revenue This Year
- VRAX $217,274.83
- EVAX N/A
- Revenue Next Year
- VRAX N/A
- EVAX $425.50
- P/E Ratio
- VRAX N/A
- EVAX N/A
- Revenue Growth
- VRAX N/A
- EVAX 1042.45
- 52 Week Low
- VRAX $0.52
- EVAX $1.20
- 52 Week High
- VRAX $3.62
- EVAX $16.55
- Technical
- Relative Strength Index (RSI)
- VRAX 46.78
- EVAX 54.67
- Support Level
- VRAX $0.59
- EVAX $2.81
- Resistance Level
- VRAX $0.70
- EVAX $3.04
- Average True Range (ATR)
- VRAX 0.05
- EVAX 0.22
- MACD
- VRAX 0.01
- EVAX 0.00
- Stochastic Oscillator
- VRAX 69.66
- EVAX 76.61
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.